💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Canagliflozin

CHEMBL4594217 Phase 4 승인됨 Small molecule
Half-Life
10.6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
444.5 g/mol
LogP
3.2
Phase
4

An SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by preventing the kidneys from reabsorbing glucose, causing it to be excreted in the urine. Beyond glucose control, it reduces the risk of cardiovascular events and slows progression of diabetic kidney disease. Side effects include urinary and genital infections and a rare risk of lower limb amputation.

분자량

444.5170 g/mol

LogP

3.20

TPSA

118.00 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Gout HIV/AIDS Heart Failure Prostate Cancer Colorectal Cancer

약물 분류

A — A - Alimentary Tract and Metabolism

작용 기전

Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

Pharmacokinetics (PK)

Half-Life 10.6 hours

Pharmacodynamics (PD)

기전

Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O

                

                

                
                

                    
InChI

                    
InChI=1S/C24H25FO5S.H2O/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14;/h2-10,19,21-24,26-29H,11-12H2,1H3;1H2/t19-,21-,22+,23-,24+;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H25FO5S

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
회전 가능 결합

                        
5

                    

                    
                    
                    

                        
무거운 원자

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
An SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by preventing the kidneys from reabsorbing glucose, causing it to be excreted in the urine. Beyond glucose control, it reduces the risk of cardiovascular events and slows progression of diabetic kidney disease. Side effects include urinary and genital infections and a rare risk of lower limb amputation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Canagliflozin: Half-life: 10.6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Canagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4594217.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24812758.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.